Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update

Hims & Hers Health, Inc. (NYSE:HIMS) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 31,870,000 shares, a growth of 28.7% from the September 30th total of 24,760,000 shares. Currently, 18.3% of the shares of the company are short sold. Based on an average daily volume of 9,830,000 shares, the short-interest ratio is currently 3.2 days.

Hims & Hers Health Trading Up 5.8 %

Shares of NYSE:HIMS traded up $1.26 during midday trading on Monday, hitting $22.99. 4,531,986 shares of the stock were exchanged, compared to its average volume of 8,168,695. The stock has a market cap of $4.94 billion, a P/E ratio of 287.41 and a beta of 1.06. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a 50 day moving average price of $17.59 and a 200-day moving average price of $17.88.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the previous year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health will post 0.22 earnings per share for the current year.

Insider Activity

In other news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the sale, the insider now directly owns 193,980 shares of the company’s stock, valued at approximately $4,306,356. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the completion of the sale, the insider now directly owns 193,980 shares of the company’s stock, valued at $4,306,356. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,334 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the sale, the insider now directly owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 841,076 shares of company stock valued at $14,759,219. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC grew its holdings in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC grew its holdings in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC grew its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank grew its holdings in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of several analyst reports. Bank of America upped their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. TD Cowen boosted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Finally, Piper Sandler reiterated a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.